Drugs / Clioquinol

Trials 3

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00963495 Aug 2009 → Sep 2013 Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, myelodysplastic syndrome +1 University Health Network, Toronto Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT05727943 Mar 2022 → Dec 2023 epilepsy KU Leuven Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT01429701 May → Jun 2012 dermatitis EMS Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Clioquinol ClinicalTrials.gov intervention name — accepted as the source's own label NCT05727943 ↗
2

NCT00963495 ↗

NCT01429701 ↗

Known as 4-stearylamino-phenyl-trimethylam. metilsulf. ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗
Known as Clioquinol component of nystaform ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗
Known as Iodochlorhydroxyquin ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗
Known as Iodochlorhydroxyquinolone ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗
Known as NSC-3531 ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗
Known as NSC-74938 ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗
Known as Oralcer ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗
Known as Vioform ChEMBL registry synonym — accepted as the source's own label CHEMBL497 ↗
Modality Small molecule — CHEMBL497 ↗
Route Oral “Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy” NCT00963495 ↗